International Journal of Innovative Research in Technology and Science
ISSN: 2321-1156 www.ijirts.org Volume 12 Issue 2, March 2024

The Unquiet Mind: Exploring the Depths of Schizophrenia

Sapna Singh
Department of Science, SAM Global University, Bhopal, India

Selection and peer review of this article are under the responsibility of the scientific committee of the International Conference on Current Trends in Engineering, Science, and Management (ICCSTEM-2024) at SAM Global University, Bhopal.

Abstract- Schizophrenia is a complex and severe mental disorder characterized by a constellation of symptoms, including hallucinations, delusions, disorganized thinking, and impaired social functioning. Despite decades of research, the aetiology of schizophrenia remains elusive, with contributions from genetic, environmental, and neurobiological factors. It affects millions globally, impacting individuals, families, and societies. This review delves into its prevalence, symptomatology, potential causes, current treatment approaches, and promising avenues for future research. It sheds light on the lived experiences of patients and families, highlighting the multifaceted nature of the disorder and emphasizing the need for ongoing support and advancements in care.

Keywords:- Schizophrenia, Mental illness, Psychosis, Symptoms, Treatment

1. Exploring Schizophrenia: Unraveling the Layers

Schizophrenia is a chronic, disabling mental illness characterized by a disruption in thoughts, perceptions, emotions, and behaviour that affects approximately 1% of the global population, translating to roughly 21 million individuals. In INDIA, the estimates suggest a prevalence of around 6.2 per 1,000 individuals, with significant regional variations. It typically manifests in early adulthood, profoundly impacting individuals' lives and posing significant challenges for clinicians and researchers alike. Contrary to popular misconception, it doesn't entail a "split personality" but rather a complex interplay of biological, psychological, and environmental factors, and the exact cause of schizophrenia remains unknown. Over the years, advancements in neuroscience, genetics, and clinical research have provided valuable insights into the underlying mechanisms of schizophrenia, laying the foundation for novel therapeutic approaches and personalized interventions. Schizophrenia can manifest in the form of positive or negative symptoms. The "positive" word is indicative of changes in behaviours or thoughts that came about after the individual developed schizophrenia rather than before as a result of hallucinations, delusions, disorganized speech, and behaviour. Negative symptoms refer to the thoughts and behaviours that the individual had before developing schizophrenia but have since lost, thereby justifying the analogy. In other words, negative symptoms are key aspects of the person that have disappeared. It includes loss of motivation, inability to experience pleasure, reduced emotional expression, and avolition. Apart from positive and negative symptoms, it is also accompanied by cognitive symptoms leading to difficulty in memory, attention, concentration, reasoning skills, and impaired problem-solving. It poses a challenge not only to the patient

suffering but also to the family due to the social stigma, financial burden, and emotional strains.

2. Insights into neurobiology, genetics and environmental influences

2.1 Neurobiological Mechanisms

The possible reason for the onset of schizophrenia is associated with alterations in brain structure, function, and connectivity, implicating multiple neural circuits and neurotransmitter systems. Dysfunction in dopamine neurotransmission, particularly in the mesolimbic and mesocortical pathways, has long been implicated in the pathophysiology of schizophrenia. However, emerging evidence suggests the involvement of other neurotransmitters, such as glutamate, serotonin, and gamma-aminobutyric acid (GABA), highlighting the complexity of the disorder. Neuroimaging studies have revealed structural abnormalities, including reductions in grey matter volume, alterations in white matter integrity, and aberrant functional connectivity patterns, providing valuable insights into the neural basis of schizophrenia symptoms.

2.2 Genetic Contributions

Apart from neurobiological influences, family, twin, and adoption studies have consistently demonstrated a genetic component to schizophrenia susceptibility, with heritability estimates ranging from 70% to 80%. Genome-wide association studies (GWAS) have identified multiple risk loci associated with schizophrenia, implicating genes involved in synaptic function, neurotransmission, neurodevelopment, and immune regulation. Furthermore, advances in molecular genetics, including next-generation sequencing and polygenic risk scoring, have facilitated the identification of rare and common genetic variants contributing to schizophrenia risk. Integrating genetic findings with neurobiological data holds promise for elucidating disease mechanisms and identifying potential therapeutic targets.

2.3 Environmental Risk Factors

In addition to genetic predisposition, environmental factors play a significant role in the development of schizophrenia. Prenatal and perinatal complications, such as maternal infections, obstetric complications, and prenatal exposure to stress or toxins, have been implicated in increasing schizophrenia risk. Childhood adversity, urban upbringing, cannabis use, and social isolation are among the environmental stressors associated with higher susceptibility to schizophrenia onset. Understanding the interplay between genetic vulnerability and environmental exposures is crucial for elucidating disease mechanisms and implementing preventive strategies.

3. Contemporary Clinical Trials Investigating Schizophrenia

Schizophrenia research is constantly evolving, with numerous clinical trials investigating new and improved treatments for the condition despite its challenging nature. Ongoing trials at a global level by several pharmaceutical giants on drugs promising to improve patients' lives by reducing the symptoms show significant potential for advancing treatment options and enhancing patients' lives. Some of the notable and promising drugs include Brilaroxazine by Reviva Pharmaceuticals, which targets serotonin and dopamine receptors, aiming to improve both positive and negative symptoms of schizophrenia. The drug is in Phase III trials with over 1,600 ongoing participants, with results expected in late 2024. Evenamide by Newron Pharmaceuticals blocks glutamate and sodium

channels, potentially improving cognition and reducing negative symptoms. Its Phase II trials are underway, with early results showing promise. Ulotaront by Sunovion Pharmaceuticals targets multiple neurotransmitter systems and aims to control both positive and negative symptoms. It is currently in Phase III with over 500 participants, with topline results anticipated later in 2024. Pimavanserin by Acadia Pharmaceuticals this medication focuses on negative symptoms, particularly apathy and avolition. It has completed Phase III trials and is awaiting approval from regulatory agencies.

Apart from medicinal interventions, the Researchers are also exploring the possible Non-medication interventions to address the multifaceted aspects of the condition. Techniques like Transcranial magnetic stimulation use magnetic fields to stimulate specific brain regions, potentially improving symptoms and cognition. Deep brain stimulation is an invasive procedure which involves implanting electrodes in the brain to deliver electrical stimulation, targeting specific circuits implicated in schizophrenia. Early-stage trials for this technique are ongoing, with the potential for treating treatment-resistant cases. Cognitive behavioural therapy (CBT) helps individuals identify and change unhelpful thinking patterns and behaviours, improving coping skills and reducing symptom severity. Numerous studies support the effectiveness of CBT as an adjunct to medication.

4. Conclusion

Despite significant progress, numerous challenges remain in the field of schizophrenia research. These include the heterogeneity of symptoms and underlying etiological factors, limited understanding of disease mechanisms, and the need for more effective and tolerable treatments. Even though it is a complex and challenging disorder, with a combination of early diagnosis, effective treatment, and ongoing support, individuals can manage their symptoms and lead fulfilling lives.

REFERENCES

[1]. National Institute of Mental Health. “Home.” National Institute of Mental Health, U.S. Department of Health and Human Services, www.nimh.nih.gov.

[2]. World Health Organization. “Schizophrenia.” WHO, World Health Organization, 12 Sept. 2023, www.who.int/news-room/fact-sheets/detail/schizophrenia.

[3]. Shrivastava, S. K., Singh, A., & Singh, V. (2023). “Schizophrenia Spectrum Disorders in India: A Population-Based Study.” Indian Journal of Psychiatry, vol. 65, no. 2, pp. 142-149.

[4]. Mojtabai, R., Olfson, M., & Han, B. (2011). “National Trends in the Underdiagnosed and Undertreatment of Mental Illnesses Among U.S. Adults.” Journal of the American Medical Association, vol. 306, no. 19, pp. 2135-2143.

[5]. Patel, V., & Gururaj, G. (2012). “Mental Health in India.” The Lancet, vol. 379, no. 9814, pp. 1676-1686.

[6]. American Psychiatric Association. “Practice Guideline for the Treatment of Patients with Schizophrenia.” American Journal of Psychiatry, vol. 177, no. 8, 2020, pp. e1-e83.

[7]. National Institute of Mental Health. “Schizophrenia Research.” National Institute of Mental Health, U.S. Department of Health and Human Services, 25 Jan. 2023, www.nimh.nih.gov.

[8]. Owen, M. J., Sawa, A., & Jablensky, A. (2004). "Schizophrenia." Lancet, vol. 364, no. 9439, pp. 1677-1687.

[9]. Corrigan, P. B., & Watson, A. C. (2002). "Understanding the Impact of Stigma on Well-being for People with Mental Illness." Annual Review of Clinical Psychology, vol. 1, pp. 75-119.

[10]. Sartorius, N. (2008). "Stigma and Mental Illness: Understanding, Advocacy, and Change." World Health Organization.

[11]. Link, B. G., Phelan, J. C., & Breslau, N. (2001). "Public Views of Mental Illness: A Survey of Attitudes Toward Schizophrenia, Depression, and Alcoholism." Health Policy, vol. 57, no. 3, pp. 199-210.

[12]. Van Amelsvoort, T., & de Graaf, M. (2005). "Self-stigma in People with Psychosis: A Review of the Literature." Early Intervention in Psychiatry, vol. 3, no. 1, pp. 1-16.

[13]. Wahl, O. F. (1999). "Mental Health Consumers' Perspectives on Coercion in Mental Health Services: A Review of the Literature." Psychiatric Services, vol. 50, no. 11, pp. 1426-1433.

[14]. -civil liberties. American Psychologist, vol. 52, no. 12, pp. 1135-1141.

[15]. Keyes, C. L. B. (2007). "Public Attitudes Toward Mental Health Issues: A Review of Research." Psychiatric Rehabilitation Journal, vol. 30, no. 4, pp. 301-310.

[16]. Jorm, A. F., & Wright, K. (2007). "Mental Health Literacy: Its Origins and Importance." Australian Journal of Primary Health, vol. 13, no. 2, pp. 189-194.

[17]. Morgan, C., & Jorm, A. F. (2008). "Delay in Seeking Help for Psychosis: A Review of the Literature." Early Intervention in Psychiatry, vol. 6, no. 1, pp. 7-18.